ArticleJournal of general internal medicine2005
The corporate coauthor.
Article in Journal of general internal medicine, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Antidepressants and breast and ovarian cancer risk: a review of the literature and researchers' financial associations with industry.PloS one · 2011Pooled it
- How big is the medical writing industry? Why it matters.Health promotion international · 2025Article
- Medicines Information and the Regulation of the Promotion of Pharmaceuticals.Science and engineering ethics · 2019Article
- Evidence Regarding the Impact of Conflicts of Interest on Environmental and Occupational Health Research.Current environmental health reports · 2017Review
- Of mugs, meals and more: the intricate relations between physicians and the medical industry.Medicine, health care, and philosophy · 2013Article
- On markets and morals--(re-)establishing independent decision making in healthcare: a reply to Joao Calinas-Correia.Medicine, health care, and philosophy · 2013Article
- Those who have the gold make the evidence: how the pharmaceutical industry biases the outcomes of clinical trials of medications.Science and engineering ethics · 2012Article
- Promoting transparency in pharmaceutical industry-sponsored research.American journal of public health · 2012Article
- The haunting of medical journals: how ghostwriting sold "HRT".PLoS medicine · 2010Article
- Estrogen implants: embodiments of deeper problems in the marketing of drugs.Journal of general internal medicine · 2010Article
- Of sophists and spin-doctors: industry-sponsored ghostwriting and the crisis of academic medicine.Mens sana monographs · 2010Article
- Five years before the masthead: our journey with the Journal of General Internal Medicine.Journal of general internal medicine · 2009Article
- Obesity, the endocannabinoid system, and bias arising from pharmaceutical sponsorship.PloS one · 2009Article
- Medical ghost-writing.Mens sana monographs · 2008Article
- Biomedical research and corporate interests: a question of academic freedom.Mens sana monographs · 2008Article
- Ghost management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry?PLoS medicine · 2007Review
- The corporate co-author, the ghostwriter, and the medical society: an object lesson (June, 2005 issue).Journal of general internal medicine · 2006Article
- Comments on "The corporate author".Journal of general internal medicine · 2005Article
- Response to "the corporate coauthor".Journal of general internal medicine · 2005Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug marketing techniques include the sponsorship of articles signed by academic physicians or researchers and submitted to peer-reviewed medical journals. Some of these articles are authored or coauthored by ghostwriters who work for pharmaceutical companies or medical education companies hired by pharmaceutical companies. Conflicts of interest may be difficult to detect in the subset of articles and presentations sponsored by pharmaceutical companies that never mention the targeted drug, but focus on stimulating the perceived need for the targeted drug or highlighting problems with competing drugs. The current voluntary standards for declaring conflicts of interest to readers of medical journals and audiences at medical conferences are inadequate. A public database that contains conflicts of interest of physicians and researchers would be useful.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.